Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael R. Cook"'
Autor:
Michael R. Cook, Lacey S. Williams, Charles Scott Dorris, Yutong Luo, Kepher Makambi, Kieron Dunleavy
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathologic entity. Currently, there is a paucity of randomized prospective data to inform on optimal front-line chemoimmunotherapy (CIT) and use of consolidative mediastinal radiation (
Externí odkaz:
https://doaj.org/article/6bc0c9affa76423aa426f460a410964e
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 301-313 (2022)
Abstract The natural history of patients with myelodysplastic syndrome (MDS) is dependent upon the presence and magnitude of diverse genetic and molecular aberrations. The International Prognostic Scoring System (IPSS) and revised IPSS (IPSS‐R) are
Externí odkaz:
https://doaj.org/article/2648363954a243749afc7c304250dcc5
Autor:
Michael R. Cook, Kaitlyn Dykes, Katherine White, Sameer Desale, Rajeev Agrawal, Stephen Fernandez, Xu Huang, Nathan K. Cobb, Catherine Lai
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background : Venous thromboembolism (VTE) is a common complication in acute COVID-19 and those with hematologic malignancy (HM) may be at an even higher risk. We performed a retrospective analysis of patients with history of HM and acute COVID-19 to
Autor:
Michael R. Cook, Kieron Dunleavy
Publikováno v:
Current Oncology Reports. 24:1121-1131
Publikováno v:
eJHaem. 3:301-313
The natural history of patients with myelodysplastic syndrome (MDS) is dependent upon the presence and magnitude of diverse genetic and molecular aberrations. The International Prognostic Scoring System (IPSS) and revised IPSS (IPSS-R) are the most w
Autor:
Ghassan Al-Shbool, Michael B. Atkins, Michael R. Cook, Geoffrey T. Gibney, Matthew Blackburn, Anas Belouali, Stephen V. Liu, Neil J. Shah, Aiwu Ruth He, Chul Kim, Subha Madhavan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
s Background Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI therapy in patients with both c